Therapeutic Antibodies

Antibody-drug conjugate
#Antibody drug conjugate (ADC) #Collaboration #ProBio #Therapeutic Antibodies

ProBio and AbTis partner on next-generation antibody-drug conjugate

CRDMO ProBio and South Korean biotechnology company AbTis have agreed an exclusive global licensing agreement for the development of antibody-drug conjugates (ADCs).  AbTis will receive exclusive global rights to develop and commercialise a discovery-stage therapeutic antibody asset generated through ProBio’s biologics discovery and development capabilities against an… Read More

#Business & Investment #News

IgG1 monoclonal antibody
#Autoimmune disease #Phase I trial #Therapeutic Antibodies #Viridian Therapeutics

FcRn inhibitor demonstrates sustained IgG reduction in Phase I trial

Viridian Therapeutics has announced positive Phase I trial results for VRDN-008, a half-life extended bifunctional FcRn inhibitor licensed from Paragon Therapeutics.  In the trial, VRDN-008 demonstrated a potential best-in-class pharmacokinetic (PK) and pharmacodynamic (PD) profile with the potential to be dosed every eight weeks.   VRDN-008… Read More

#News

#AI / data analytics / healthtech / informatics #Artificial intelligence (AI) #Therapeutic Antibodies

From AI design to experimental validation: The next frontier in antibody discovery

This article is sponsored by GenScript. Integration of artificial intelligence (AI) into antibody drug discovery is occurring in phases, as AI models mature, and developers seek to compress discovery and development timelines. While increasingly iterative and feedback-driven approaches to AI-driven antibody discovery have made the process more efficient,… Read More

#Exclusive Content

Antibodies
#License agreement #Roche #T cell engagers #Therapeutic Antibodies #Zymeworks

Roche licenses Zymeworks’ trispecific T cell engager targeting DLL3

Zymeworks has entered into a global license and collaboration agreement with Roche for the research, development and commercialisation of ZW209, a T cell engager targeting DLL3.  Under the agreement, Zymeworks is eligible to receive an upfront payment of $55 million, a $40 million payment upon initiation of… Read More

#Business & Investment #News

Antibody discovery concept
#Artificial intelligence (AI) #Biologics #Drug discovery #Therapeutic Antibodies #Webinar

Webinar: Modernise and scale your antibody discovery programmes

Antibody discovery is being reshaped by two forces: an explosion of novel formats and the growing role of AI across the DBTL loop. But most teams are still running antibody programs on software that hasn’t kept pace with science, leaving data siloed and relationships missing. In this webinar, hosted by… Read More

Webinar date:
Supported by Benchling
#News

Antibodies
#Artificial intelligence (AI) #Biologics #Drug discovery #Therapeutic Antibodies #Webinar

Webinar: Meet the challenges of a shifting antibody discovery landscape

Antibody discovery is being reshaped by two forces: an explosion of novel formats and the growing role of AI across the DBTL loop. But most teams are still running antibody programs on software that hasn’t kept pace with science, leaving data siloed and relationships missing. In this webinar, hosted by… Read More

Webinar date:
Supported by Benching
#News

Antibodies
#Artificial intelligence (AI) #Biologics #Drug discovery #Therapeutic Antibodies #Webinar

Webinar: Discover a modern data foundation for complex biologics

Antibody discovery is being reshaped by two forces: an explosion of novel formats and the growing role of AI across the DBTL loop. But most teams are still running antibody programs on software that hasn’t kept pace with science, leaving data siloed and relationships missing. In… Read More

Webinar date:
Supported by Benching
#News

Monoclonal antibody
#Artificial intelligence (AI) #Biologics #Drug discovery #Therapeutic Antibodies #Webinar

Webinar: Discover AI infrastructure for modern antibody discovery

Antibody discovery is being reshaped by two forces: an explosion of novel formats and the growing role of AI across the DBTL loop. But most teams are still running antibody programmes on software that hasn’t kept pace with science, leaving data siloed and relationships missing. In this webinar on 11… Read More

Webinar date:
Supported by Benching
#News

Antibody discovery concept
#Artificial intelligence (AI) #Biologics #Drug discovery #Therapeutic Antibodies #Webinar

Introducing Benchling Biologics: AI infrastructure for modern drug discovery

Antibody discovery is being reshaped by two forces: an explosion of novel formats and the growing role of AI across the DBTL loop. But most teams are still running antibody programmes on software that hasn’t kept pace with science, leaving data siloed and relationships missing. In this webinar, hosted by… Read More

Webinar date:
Supported by Benching
#News

Antibody discovery concept
#Artificial intelligence (AI) #Biologics #Drug discovery #Therapeutic Antibodies #Webinar

Introducing Benchling Biologics: AI infrastructure for modern drug discovery

Antibody discovery is being reshaped by two forces: an explosion of novel formats and the growing role of AI across the DBTL loop. But most teams are still running antibody programmes on software that hasn’t kept pace with science, leaving data siloed and relationships missing. In this webinar on 11… Read More

Webinar date:
Supported by Benchling
#Webinars